Study of Henagliflozin for Type 2 Diabetes
Part of Hormones & metabolism clinical trials.
This study tests how safe and effective the diabetes medication henagliflozin is for Chinese patients with type 2 diabetes. It is an observational study, meaning you will continue your regular care while researchers watch your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have type 2 diabetes and are currently taking or could add henagliflozin to your treatment.
- You are willing to sign a consent form (a helper can sign for you if needed).
- You have not taken part in another diabetes drug study in the last month.
- You do not have a history of repeated urinary tract or genital infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of managing type 2 diabetes: taking the drug dapagliflozin with a continuous glucose monitor (a small sensor that tracks sugar levels) versus traditional finger-prick testing. It aims to see if using the monitor helps control blood sugar better.
This trial tests a new combination pill (henagliflozin and metformin) compared to metformin alone in people recently diagnosed with type 2 diabetes. The goal is to see which treatment works better and is safer.
This study tests a new diabetes pill called henagliflozin to see if it helps smooth out blood sugar ups and downs and may also slow aging of the immune system in people with type 2 diabetes who are already on insulin. It is for adults aged 50–70 whose blood sugar is still high despite insulin therapy.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.